Catena Biosciences GTM brain

category

market profile

• text: The company focuses its multi-payload conjugates initially on solid tumors and describes its evidence as preclinical.
• text: Potential partners can explore the platform for novel R&D pipelines, alongside Catena's own therapeutic development.

personas

• title: Oncology R&D or ADC program leader
  pains:

  • Single-payload therapies can encounter resistance
  • Conventional conjugation limits payload choice and control
• title: Biopharma business development lead
  pains:

  • Finding differentiated oncology assets with credible preclinical data
  • Balancing platform licensing opportunity against technical and clinical risk
• title: Antibody engineering scientist
  pains:

  • Premature linker release may reduce targeting and increase off-target exposure
  • Need to control conjugation sites and drug-to-antibody ratio

icp

• text: Biotechnology and pharmaceutical organizations developing antibody-based oncology candidates, especially solid tumor programs.
• text: R&D partners seeking novel conjugation modalities for biologics pipelines; account size is not specified.

message pillars

• text: Multiple payload types can be placed on one antibody.
• text: The chemistry aims to accommodate diverse payload sizes.
• text: A more stable bond is positioned to reduce release away from the target.

objections

• objection: Preclinical results may not translate to human efficacy or safety.
  response: Review the underlying comparative studies, clinical development plan and data as they become available.
• objection: A new conjugation approach may be hard to manufacture at scale.
  response: Request process-transfer, yield and manufacturing evidence relevant to the specific construct.

competitors

• name: Mersana Therapeutics
  why: ADC developer named as a possible alternative by Crunchbase.
• name: AbCellera
  why: Biologics discovery partner identified as a possible alternative by Crunchbase, though broader than ADC conjugation.

influencers

• name: Marco Lobba
  url: https://www.linkedin.com/in/marco-lobba
  why: Co-founder and CEO with a background in protein conjugation.

keywords

• site specific antibody drug conjugation
• multi payload ADC
• ADC linker stability
• protein protein conjugation platform
• solid tumor ADC development
• conjugation technology licensing

voice

• scientific and mechanism-led
• ambitious but preclinical

signals

• text: A pharma R&D team is launching a solid tumor ADC program or evaluating alternative payloads.
• text: A biotech seeks external conjugation technology for an existing antibody pipeline.

pricing

motion

channels

• scientific conferences
• publications
• biopharma partnerships

confidence

Founders

• name: Marco Lobba
  title: Founder
  role: Founder
  bio: CEO and Co-Founder at Catena Biosciences. Marco completed his Ph.D. at UC Berkeley jointly between the labs of Matt Francis and Jennifer Doudna. When not starting a company or doing science Marco likes to backpack, rock climb, kayak, and just about any activity that involves not being inside.
• name: Matthew Francis
  title: Founder
  role: Founder